Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036602 | 1.00 | FGFR1 (0.66) | FGFR1HTTSRCALDH1A1KDR | |
| SCHEMBL10986832 | 0.86 | HTT (0.62) | FGFR1HTTSRCALDH1A1 | |
| SCHEMBL14251078 | 0.84 | FGFR1 (0.53) | FGFR1HTTALDH1A1 | |
| SCHEMBL38651826 | 0.83 | FGFR1 (0.62) | FGFR1ALDH1A1 | |
| SCHEMBL17149333 | 0.83 | FGFR1 (0.62) | FGFR1HTTALDH1A1 | |
| SCHEMBL9951044 | 0.83 | FGFR1 (0.61) | FGFR1ALDH1A1 | |
| SCHEMBL38651874 | 0.83 | FGFR1 (0.61) | FGFR1ALDH1A1 | |
| SCHEMBL24614567 | 0.82 | FGFR1 (0.68) | FGFR1SRCALDH1A1 | |
| SCHEMBL23846263 | 0.81 | FGFR1 (0.76) | FGFR1HTTSRCALDH1A1 | |
| SCHEMBL17152727 | 0.81 | HPGD (0.54) | FGFR1ALDH1A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112239452-B | Electron transport type heteroanthracene derivative and organic electroluminescent device thereof | 武汉尚赛光电科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-112239452-A | Electron transport type heteroanthracene derivative and organic electroluminescent device thereof | 武汉尚赛光电科技有限公司 | 2021-01-19 | — | — | CN | disclosed |
| EP-3110803-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Mutabilis (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| WO-2015128333-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LABORATOIRE BIODIM (FR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| WO-2013148603-A1 | CINNOLINE DERIVATIVES AS AS BTK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | WO | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-6465484-B1 | TYROSINE KINASE INHIBITORS; CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1109555-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1109555-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6162804-A | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000012089-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | FGFR1 163/4885HTT 513/4885SRC 234/4885 |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | BTK, LYN, ABL1 | FGFR1 1035/4885HTT 3454/4885SRC 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.